High home prices aren’t sidelining buyers in some cities. In the 10 markets where offers came in the fastest — as few as 16 ...

Shares of Keysight Technologies climbed after the company raised its full-year outlook and beat analysts expectations in its second-quarter earnings. Shares of the test equipment maker rose 5.8% to ...

Cipher Mining shares were down 10% to $3.40 after the company priced a public offering of $150 million of convertible senior notes due 2030 in an offering. The issuance and sale of the notes are ...

U.S. crude oil inventories rose for a second consecutive week, while stocks of gasoline and diesel increased amid higher refinery capacity use, according to data released Wednesday by the U.S. Energy ...

Oil prices turned lower Wednesday as weekly data showing a rise in U.S. crude supplies outweighed earlier support brought on by reports that U.S. intelligence suggested [Israel was making preparations ...

Legislation regulating stablecoins, a type of cryptocurrency whose value is pegged to another asset, is set for a vote in the ...

U.S. stocks were again under pressure on Wednesday morning as investors closely monitored another move higher in Treasury ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

A slowdown in drilling activities in the Permian Basin, the largest U.S. shale oil production region, should provide some underlying support to the price of crude oil, Goldman Sachs said in its most ...

Last week, CN Rail said it aimed to invest C$3.4 billion in maintaining and expanding its rail network in North America. The capital program for the year includes roughly C$2.9 billion allocated to ...

Mirion Technologies shares were 5% higher, at $18.37, after the company priced $350 million of 0.25% convertible senior notes due 2030 in a private placement. The size of the offering was increased ...

Shares of Sarepta Therapeutics advanced after the company said it has received the go-ahead from U.K. regulators to keep dosing in a study of its Elevidys treatment for Duchenne muscular dystrophy.